[{"id":"33062010-2f9f-457a-bb48-293b21b77b51","acronym":"RAGNAR","url":"https://clinicaltrials.gov/study/NCT04083976","created_at":"2021-01-18T19:59:45.508Z","updated_at":"2025-02-25T12:37:25.290Z","phase":"Phase 2","brief_title":"A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations","source_id_and_acronym":"NCT04083976 - RAGNAR","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGFR2 • FGFR • TACC3 • TACC2","pipe":" | ","alterations":" FGFR3 mutation • FGFR mutation • FGFR fusion","tags":["FGFR2 • FGFR • TACC3 • TACC2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR3 mutation • FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 11/20/2019","start_date":" 11/20/2019","primary_txt":" Primary completion: 12/04/2023","primary_completion_date":" 12/04/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"9c7ac936-fde1-4b07-9296-dad7240ad183","acronym":"","url":"https://clinicaltrials.gov/study/NCT04963153","created_at":"2021-07-15T13:06:11.818Z","updated_at":"2025-02-25T12:28:14.832Z","phase":"Phase 1","brief_title":"Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy","source_id_and_acronym":"NCT04963153","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • FGFR2 • NECTIN4","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • FGFR2 • NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/07/2022","start_date":" 07/07/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-24"},{"id":"0fa68358-5ca0-4783-89e5-388a03a0323e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02421185","created_at":"2021-01-18T11:34:41.906Z","updated_at":"2025-02-25T16:58:47.423Z","phase":"Phase 1/2","brief_title":"Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma","source_id_and_acronym":"NCT02421185","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGF","pipe":"","alterations":" ","tags":["FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 05/25/2015","start_date":" 05/25/2015","primary_txt":" Primary completion: 05/13/2019","primary_completion_date":" 05/13/2019","study_txt":" Completion: 05/16/2019","study_completion_date":" 05/16/2019","last_update_posted":"2025-02-03"},{"id":"25d363db-b73d-42b4-a08a-717568224b15","acronym":"THOR-2","url":"https://clinicaltrials.gov/study/NCT04172675","created_at":"2021-01-18T20:21:16.432Z","updated_at":"2025-02-25T17:00:18.386Z","phase":"Phase 2","brief_title":"A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)","source_id_and_acronym":"NCT04172675 - THOR-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Balversa (erdafitinib) • mitomycin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 02/28/2020","start_date":" 02/28/2020","primary_txt":" Primary completion: 07/12/2024","primary_completion_date":" 07/12/2024","study_txt":" Completion: 03/03/2025","study_completion_date":" 03/03/2025","last_update_posted":"2025-02-03"},{"id":"5c88c63c-d256-4f58-81e6-5b70704df6d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06632262","created_at":"2025-02-26T15:04:35.295Z","updated_at":"2025-02-26T15:04:35.295Z","phase":"Phase 2","brief_title":"A Phase 2 Clinical Study of ABSK061 and ABSK043","source_id_and_acronym":"NCT06632262","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" HER-2 • FGFR2 • FGFR3","pipe":"","alterations":" ","tags":["HER-2 • FGFR2 • FGFR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABSK043 • lavengratinib (ABSK061)"],"overall_status":"Recruiting","enrollment":" Enrollment 202","initiation":"Initiation: 11/13/2024","start_date":" 11/13/2024","primary_txt":" Primary completion: 11/30/2029","primary_completion_date":" 11/30/2029","study_txt":" Completion: 06/30/2030","study_completion_date":" 06/30/2030","last_update_posted":"2024-11-19"},{"id":"5c6decd8-2f64-40a9-8da2-299c3dfe4465","acronym":"EAY131-K2","url":"https://clinicaltrials.gov/study/NCT06351371","created_at":"2025-02-27T09:37:17.782Z","updated_at":"2025-02-27T09:37:17.782Z","phase":"Phase 2","brief_title":"Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)","source_id_and_acronym":"NCT06351371 - EAY131-K2","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 07/03/2018","start_date":" 07/03/2018","primary_txt":" Primary completion: 06/02/2022","primary_completion_date":" 06/02/2022","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-10-14"},{"id":"af8ba850-b78d-4d55-8fbd-fbea3bc4dd39","acronym":"EAY131-K1","url":"https://clinicaltrials.gov/study/NCT06308822","created_at":"2025-02-27T09:19:29.964Z","updated_at":"2025-02-27T09:19:29.964Z","phase":"Phase 2","brief_title":"Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)","source_id_and_acronym":"NCT06308822 - EAY131-K1","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/20/2018","start_date":" 08/20/2018","primary_txt":" Primary completion: 07/27/2022","primary_completion_date":" 07/27/2022","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-09-16"},{"id":"1d4ba0e5-2e91-4eb0-9b78-dcfdf4bea1c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05564416","created_at":"2022-10-03T15:56:45.916Z","updated_at":"2024-07-02T16:35:16.428Z","phase":"Phase 2","brief_title":"Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial","source_id_and_acronym":"NCT05564416","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • FGFR3","pipe":" | ","alterations":" FGFR fusion","tags":["PD-L1 • FGFR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • Balversa (erdafitinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/12/2023","start_date":" 10/12/2023","primary_txt":" Primary completion: 11/03/2023","primary_completion_date":" 11/03/2023","study_txt":" Completion: 11/03/2023","study_completion_date":" 11/03/2023","last_update_posted":"2024-03-05"},{"id":"45391173-bfa1-492f-828d-d0cb5112e61f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03238196","created_at":"2021-01-17T17:26:50.151Z","updated_at":"2024-07-02T16:35:21.276Z","phase":"Phase 1","brief_title":"Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer","source_id_and_acronym":"NCT03238196","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" HER-2 • ER • FGFR2 • FGFR1 • FGFR4 • FGF23","pipe":" | ","alterations":" HER-2 negative • FGFR1 amplification • FGFR3 amplification • FGFR4 amplification • FGFR amplification","tags":["HER-2 • ER • FGFR2 • FGFR1 • FGFR4 • FGF23"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • FGFR1 amplification • FGFR3 amplification • FGFR4 amplification • FGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Balversa (erdafitinib) • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/18/2017","start_date":" 08/18/2017","primary_txt":" Primary completion: 04/30/2021","primary_completion_date":" 04/30/2021","study_txt":" Completion: 09/25/2024","study_completion_date":" 09/25/2024","last_update_posted":"2024-02-01"},{"id":"72b6e296-999e-4af6-965d-02f44a6823a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05039892","created_at":"2021-09-10T16:57:16.515Z","updated_at":"2024-07-02T16:35:21.555Z","phase":"Phase 2","brief_title":"Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma","source_id_and_acronym":"NCT05039892","lead_sponsor":"3D Medicines (Beijing) Co., Ltd.","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e segigratinib (3D185)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-01-31"},{"id":"913fa15c-9288-4cf0-a89a-f0851bfabf86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04353375","created_at":"2023-07-06T20:09:42.965Z","updated_at":"2025-02-25T14:51:46.214Z","phase":"Phase 2","brief_title":"Phase 2 Study of HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma","source_id_and_acronym":"NCT04353375","lead_sponsor":"Hutchmed","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fanregratinib (HMPL-453)"],"overall_status":"Recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 09/03/2020","start_date":" 09/03/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-07-06"},{"id":"934d3478-921a-4635-9f03-493d15ba270a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05244551","created_at":"2022-02-17T18:22:17.151Z","updated_at":"2024-07-02T16:36:00.316Z","phase":"Phase 1","brief_title":"A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05244551","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR3 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR3 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lavengratinib (ABSK061)"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2022-11-16"},{"id":"d4d894ac-2658-4499-8ad7-5be03852e67a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05173142","created_at":"2021-12-29T13:53:45.797Z","updated_at":"2025-02-25T14:52:10.343Z","phase":"Phase 1/2","brief_title":"HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors","source_id_and_acronym":"NCT05173142","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" FGFR","pipe":" | ","alterations":" PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • docetaxel • Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr) • fanregratinib (HMPL-453)"],"overall_status":"Recruiting","enrollment":" Enrollment 141","initiation":"Initiation: 01/22/2022","start_date":" 01/22/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2022-03-08"},{"id":"13fa7fc5-9e27-4fe9-afc8-5f930b506cbe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04290325","created_at":"2021-01-18T20:49:08.472Z","updated_at":"2025-02-25T14:51:42.306Z","phase":"Phase 2","brief_title":"HMPL-453 in Advanced Malignant Mesothelioma","source_id_and_acronym":"NCT04290325","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fanregratinib (HMPL-453)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 12/30/2019","start_date":" 12/30/2019","primary_txt":" Primary completion: 11/30/2022","primary_completion_date":" 11/30/2022","study_txt":" Completion: 03/17/2023","study_completion_date":" 03/17/2023","last_update_posted":"2020-06-16"},{"id":"43be2725-ea91-441b-9161-069f076f83cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03160833","created_at":"2021-01-18T15:34:57.868Z","updated_at":"2025-02-25T14:50:32.155Z","phase":"Phase 1/2","brief_title":"A Study of HMPL-453 in Patients With Advanced Solid Malignancies","source_id_and_acronym":"NCT03160833","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fanregratinib (HMPL-453)"],"overall_status":"Unknown status","enrollment":" Enrollment 33","initiation":"Initiation: 05/23/2017","start_date":" 05/23/2017","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 06/30/2020","study_completion_date":" 06/30/2020","last_update_posted":"2020-02-13"},{"id":"bad33fae-f9c7-474e-879f-6eabe449864a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02038673","created_at":"2021-01-18T09:21:26.925Z","updated_at":"2024-07-02T16:37:05.880Z","phase":"Phase 1","brief_title":"An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors","source_id_and_acronym":"NCT02038673","lead_sponsor":"Astellas Pharma Inc","biomarkers":" FGF19 • FGF23","pipe":"","alterations":" ","tags":["FGF19 • FGF23"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASP5878"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 11/05/2013","start_date":" 11/05/2013","primary_txt":" Primary completion: 07/19/2017","primary_completion_date":" 07/19/2017","study_txt":" Completion: 07/19/2017","study_completion_date":" 07/19/2017","last_update_posted":"2018-10-22"}]